
Longevity Research Pillar
Cellular Longevity: Telomere Biology, Mitochondrial Peptides, and the NAD+ Cofactor
Longevity research has matured from a fringe interest into a structured biological framework: the nine "hallmarks of aging" (López-Otín et al., 2013, updated 2023) catalogue the cellular processes whose decline causes biological aging. Peptide and small-molecule research compounds map onto specific hallmarks — telomere attrition, mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence — and the research literature has organized itself around which compounds intersect which hallmarks.
Three compounds dominate the longevity-peptide research space: Epithalon for telomerase and pineal-axis biology, MOTS-c for mitochondrial-derived peptide signaling, and NAD+ as the rate-limiting cofactor for sirtuin-mediated aging-pathway regulation. They are mechanistically distinct, address different hallmarks, and the published literature studies them as separate compounds.
Epithalon: the pineal tetrapeptide and telomerase research
Epithalon (Epitalon, Epithalamin) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the St. Petersburg Institute of Bioregulation and Gerontology. Its primary research interest is telomerase activation — published work shows upregulation of telomerase reverse transcriptase (TERT) expression and telomere lengthening in human somatic cell culture and rodent models. The implications for the telomere-attrition hallmark of aging are direct: cells with longer telomeres divide more times before reaching replicative senescence.
Beyond telomere biology, Epithalon shows pineal-axis effects in published rodent research — shifts in melatonin secretion patterns in aged animals toward profiles seen in younger animals, with corresponding changes in circadian rhythm regularity and sleep architecture. The pineal-aging hypothesis (which informed the original Russian research program) frames the pineal gland as a master regulator of biological aging tempo.
MOTS-c: the mitochondrial-derived peptide
MOTS-c is one of the more recently-discovered peptide classes (Cobb et al., 2015, USC). It is encoded entirely within the mitochondrial genome — a 16-amino-acid peptide whose ORF lives within the 12S rRNA region of mitochondrial DNA. This is unusual: most peptide research compounds are nuclear-genome-encoded. MOTS-c's mitochondrial origin places it at the center of the mitochondrial-dysfunction hallmark of aging.
Mechanistically, MOTS-c acts as an exercise mimetic in mouse models. It activates AMPK, drives glucose uptake into skeletal muscle, modulates mitochondrial biogenesis via PGC-1α, and produces metabolic effects analogous to caloric restriction or sustained aerobic exercise. The translational interest is the metabolic-aging intersection: insulin resistance, sarcopenia, and mitochondrial decline all converge on the AMPK pathway that MOTS-c activates.
NAD+: the rate-limiting longevity cofactor
NAD+ (nicotinamide adenine dinucleotide) is not a peptide — it is a small-molecule cofactor. But it sits at the center of longevity research because the entire sirtuin family of aging-regulating enzymes (SIRT1 through SIRT7) requires NAD+ as a cofactor to function. Sirtuins drive deacetylation of histones and metabolic regulators, govern caloric-restriction-like signaling, and are the most-studied cellular longevity regulators in the literature.
Cellular NAD+ levels decline with age — the consensus estimate is roughly a 40–60% reduction in tissue NAD+ from age 20 to age 80. As NAD+ falls, sirtuin activity falls; as sirtuin activity falls, the metabolic, mitochondrial, and DNA-repair pathways they regulate decline. This age-associated decline is the rationale for published studies of exogenous NAD+ and NAD+ precursors (NR, NMN) in aging models.
Frequently Asked Questions
How do Epithalon, MOTS-c, and NAD+ differ as research compounds?
They act on different hallmarks of aging. NAD+ is the sirtuin cofactor and is studied across sirtuin-dependent pathways; Epithalon is studied in telomere-biology and pineal-circadian models; MOTS-c in metabolic-aging and exercise-physiology models. The published literature studies them as separate compounds. LifeSpanSupply gives no combination, dosing, or administration guidance.
Is Epithalon's telomerase effect real?
Documented in cell-culture and rodent work over 20+ years of Russian-origin research; less extensively replicated in Western journals but the published mechanism is consistent. The cleanest research endpoint is telomere length measurement (qPCR or flow-FISH) — visible cellular-aging effects are slower and harder to quantify.
How do these compounds compare to GLP-1 agonists for "anti-aging" research?
Different domains. GLP-1 agonists target the metabolic-disease subset of aging biology (obesity, type-2 diabetes, cardiovascular). Cellular-longevity peptides target upstream cellular processes (telomere attrition, mitochondrial decline, NAD+ depletion) that drive metabolic aging but also drive aging in tissues GLP-1s do not address (skin, cognition, regenerative capacity).
Research products for this pillar
Longevity →All compounds referenced are chemical reagents for laboratory analysis. See our Terms & Conditions.







